BMO Capital raised the firm’s price target on Structure Therapeutics (GPCR) to $100 from $83 and keeps an Outperform rating on the shares. The firm cites the company’s positive Phase 2a data for its lead asset GSBR-1290, the analyst tells investors in a research note. BMO adds that it is encouraged by the emerging profile of Structures asset in obesity, with adverse effects profile in line with what it saw in the 8-week data and the efficacy bewing competitive with the likes of Eli Lilly’s (LLY) Orforglipron.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics 9.07M share Secondary priced at $52.50
- Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
- Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
- Structure Therapeutics announces offering of 8M American depositary shares
- Structure Therapeutics files to sell 8M ADSs representing 24M ordinary shares